NCT Number: NCT05246735
Frequency Domain Optical Imaging
This purpose of this clinical study to develop and test technology associated with near infrared (NIR) optical tomography of the breast (the use of light at NIR wavelengths to image the breast) as an adjunct to mammography and breast MRI.
Looking for future studies?
Notify MeKey information
Conditions
Age range
20 year and older
Sex eligibility
Female
Study type
Interventional
Phase
Not applicable
About this study
The purpose of this clinical study is to demonstrate the feasibility of NIR absorption and fluorescence imaging of the female breast when the method is guided by breast MRI. The hypotheses to be tested are:
- MR-guided NIR absorption and fluorescence imaging of the breast is feasible in the setting of a clinical breast exam
- MR-guided NIR absorption and fluorescence imaging of the breast provides spatial localization and contrast of a breast abnormality that is superior to NIR absorption and fluorescence tomography alone.
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
HEALTHY VOLUNTEERS
Inclusion criteria
- Female, ≥20 years old
- Breast size and epithelial integrity adequate to allow NIR imaging exams.
- Ability to provide written informed consent
- No serious associated psychiatric illnesses.
Exclusion criteria
- Absolute or relative contraindication to MRI:
- the presence of an electronic implant, such as a pacemaker
- the presence of a metal implant, such as an aneurysm clip
- claustrophobia
- the presence of other contraindication(s), as determined by the MRI technologists and radiologists.
- Pregnancy
WOMEN WITH BREAST ABNORMALITIES
Inclusion:
- Female, ≥ 20 years old.
- Breast size and epithelial integrity adequate to allow NIR imaging exams.
- Ability to provide written informed consent.
- No serious associated psychiatric illnesses.
- A recent screening mammogram that questions the presence of an abnormality, thus requiring further mammographic examination.
Exclusion:
- Absolute or relative contraindication to MRI:
- the presence of an electronic implant, such as a pacemaker
- the presence of a metal implant, such as an aneurysm clip
- claustrophobia
- the presence of other contraindication(s), as determined by the MRI technologists and radiologists.
- Pregnancy
- A history of allergy to iodides
- A GFR < 30 ml/min as determined by blood test on the day of NIR/MR imaging, or from lab results within 3 months of NIR/MR imaging.
Treatment and study plan
Primary outcomes
-
Compare spatial localization and contrast images of breast abnormalities from MR-guided NIR absorption and fluorescence tomography to NIR absorption and fluorescence tomography alone
Time frame: During imaging and evaluation by a radiologist or medical technologist, up to 90 minute
Women will participate in MR-guided NIR exams which include both MR and optical contrast agents. These imaging outcomes will be compared to exams where only the MR contrast agent is used as well as to exams where no contrast agents are administered.
Sponsors and collaborators
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Collaborators
- Dartmouth College
Registry information
Official study title
Frequency Domain Optical Imaging of Breast Cancer
Important dates
- Study start
- 2004
- Primary completion
- 2022
- Study completion
- 2022
- First posted
- Feb 18, 2022
- Registry last updated
- May 16, 2023
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Tumor-Derived FGF19
NCT06068257
Breast Cancer, Breast Diseases
Orlando, Florida, United States
View Trial DetailsAfrican Cancer Genome: GMD
NCT05754658
Breast Cancer, Breast Diseases
Philadelphia, Pennsylvania, United States
View Trial Details24GUT540 : Meeting of Breast Cancer Patients and Pathologists
NCT07040514
Breast Cancer, Breast Diseases
Lebanon, New Hampshire, United States
View Trial DetailsNeoadjuvant Pembrolizumab and Carboplatin Plus Paclitaxel for Stage I Triple-negative Breast Cancer
NCT06604858
Breast Cancer, Breast Diseases
A Coruña, Spain
View Trial Details